Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26317874 | 0.88 | DOT1L (0.41) | DOT1LPDGFRBPDGFRANCF1MET | |
| SCHEMBL24006254 | 0.85 | MET (0.43) | DOT1LPDGFRBPDGFRANCF1MET | |
| SCHEMBL26311818 | 0.83 | DOT1L (0.41) | DOT1LPDGFRBPDGFRANCF1ALDH1A1 | |
| SCHEMBL26311820 | 0.82 | GAK (0.40) | DOT1LPDGFRBPDGFRANCF1ALDH1A1 | |
| SCHEMBL25828249 | 0.82 | NCF1 (0.41) | DOT1LPDGFRBPDGFRANCF1ALDH1A1 | |
| SCHEMBL26317877 | 0.81 | DOT1L (0.38) | DOT1LPDGFRBPDGFRANCF1MET | |
| SCHEMBL26317892 | 0.81 | ALDH1A1 (0.42) | DOT1LPDGFRBPDGFRANCF1ALDH1A1 | |
| SCHEMBL26329737 | 0.81 | DOT1L (0.39) | DOT1LNCF1METALDH1A1MEN1 | |
| SCHEMBL25491134 | 0.80 | ALDH1A1 (0.56) | DOT1LNCF1ALDH1A1MEN1GLA | |
| SCHEMBL24006371 | 0.80 | ALDH1A1 (0.52) | DOT1LNCF1ALDH1A1MEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | DOT1L 3878/4885PDGFRB 996/4885PDGFRA 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.